Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$1.33
-4.3%		$1.46
$1.31
▼
$8.34
$7.73M-2.0276,320 shs280,094 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.69
+19.0%		$1.38
$0.85
▼
$2.23
$43.14M1.66537,441 shs1.68 million shs
OPTH
Optimi Health
$4.84
-2.2%		$4.80
$4.00
▼
$6.40
$28.34MN/A59,453 shs85,897 shs
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$4.80
+5.0%		$3.72
$3.07
▼
$10.00
$34.20M1.49159,396 shs712,480 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
0.00%-0.71%-5.44%-7.95%-66.10%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%+39.22%+6.77%+7.58%-3.40%
OPTH
Optimi Health
0.00%+11.99%-1.00%+16.75%+494,999,900.00%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
0.00%+17.18%+18.39%+25.90%-21.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$1.33
-4.3%		$1.46
$1.31
▼
$8.34
$7.73M-2.0276,320 shs280,094 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.69
+19.0%		$1.38
$0.85
▼
$2.23
$43.14M1.66537,441 shs1.68 million shs
OPTH
Optimi Health
$4.84
-2.2%		$4.80
$4.00
▼
$6.40
$28.34MN/A59,453 shs85,897 shs
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$4.80
+5.0%		$3.72
$3.07
▼
$10.00
$34.20M1.49159,396 shs712,480 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
0.00%-0.71%-5.44%-7.95%-66.10%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%+39.22%+6.77%+7.58%-3.40%
OPTH
Optimi Health
0.00%+11.99%-1.00%+16.75%+494,999,900.00%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
0.00%+17.18%+18.39%+25.90%-21.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.00
Hold$31.002,230.83% Upside
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.00
Buy$6.00255.03% Upside
OPTH
Optimi Health
1.50
ReduceN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ACXP, TAOX, OPTH, and NNVC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
OPTH
Optimi Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/14/2026
OPTH
Optimi Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/6/2026
NanoViricides, Inc. stock logo
NNVC
NanoViricides
Noble Financial logo
Noble Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$6.00
7/6/2026
NanoViricides, Inc. stock logo
NNVC
NanoViricides
Noble Financial logo
Noble Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$6.00
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$2.07 per shareN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
OPTH
Optimi Health
$310K89.46N/AN/AN/A∞
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$300K119.68N/AN/A$2.83 per share1.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$7.97M-$2.69N/AN/AN/AN/A-124.73%-87.48%11/11/2026 (Estimated)
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.43N/AN/AN/AN/A-87.90%-78.69%N/A
OPTH
Optimi Health
-$1.12M-$0.76N/AN/AN/AN/AN/AN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
-$28.74M-$3.85N/AN/AN/A-2,153.97%-128.51%-97.54%N/A

Latest ACXP, TAOX, OPTH, and NNVC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.3767-$0.53-$0.1533-$0.53N/AN/A
8/13/2026Q2 2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A-$1.83N/A-$1.83N/A$0.09 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
OPTH
Optimi Health
N/AN/AN/AN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
3.88
3.88
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
OPTH
Optimi Health
0.04
0.06
0.03
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A
19.98
19.98

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
OPTH
Optimi Health
N/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
10.34%

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
6.50%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.60%
OPTH
Optimi Health
N/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
45.56 million5.20 millionNo Data
NanoViricides, Inc. stock logo
NNVC
NanoViricides
725.53 million14.92 millionOptionable
OPTH
Optimi Health
95.73 millionN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
47.48 million7.28 millionN/A

Recent News About These Companies

Synaptogenix (NASDAQ:TAOX) Stock Rating Lowered by Wall Street Zen
September 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31017632
TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-appoints-bittensor-investor-and-author-mark-jeffrey-as-advisor-302820337.html
TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-set-to-join-the-russell-microcap-index-as-a-leading-public-gateway-to-decentralized-ai-302801330.html
TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation
November 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-and-yuma-asset-management-to-host-livestream-on-x-bittensor-tao-and-deai-innovation-302618425.html
Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys
November 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tradr-set-to-debut-etfs-targeting-bloom-energy-celestica-nano-nuclear-and-synopsys-302611818.html
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds
November 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-announces-initial-750-000-investment-in-yuma-asset-managements-subnet-funds-302603960.html
TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency
October 20, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-raises-bittensor-tao-holdings-to-over-54-000-tokens-largest-publicly-traded-holder-of-top-decentralized-ai-cryptocurrency-302589032.html
TAO Synergies Announces $11 Million Private Placement
October 13, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-announces-11-million-private-placement-302582503.html
TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)
September 22, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-launches-the-tao-daily-the-premier-media-platform-for-all-things-bittensor-tao-302562601.html
TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event
September 8, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-digital-assets-advisor-james-altucher-speaks-at-googles-planet-scale-consumer-ai-event-302548971.html
TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today
July 1, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-formerly-synaptogenix-begins-trading-under-new-nasdaq-stock-symbol-taox-effective-at-market-open-today-302495716.html
Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy
June 26, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-announces-name-change-to-tao-synergies-and-new-ticker-symbol-taox-for-alignment-with-ai-focused-crypto-treasury-strategy-302491852.html
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN Austin
June 26, 2025  |  kxan.comK
Synaptogenix begins TAO acquisition as part of crypto treasury strategy
June 26, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/synaptogenix-begins-tao-acquisition-as-part-of-crypto-treasury-strategy-93CH-4144284
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLA
June 26, 2025  |  ktla.comK
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking
June 24, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-announces-initial-tao-acquisition-under-crypto-treasury-strategy-appoints-bitgo-as-custodian-and-commences-yield-generation-through-staking-302489342.html
Synaptogenix Unveils TAO-Focused Crypto Treasury Plan
June 10, 2025  |  livebitcoinnews.comL
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token
June 9, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-appoints-crypto-expert-to-lead-digital-asset-treasury-strategy-focused-exclusively-on-top-valued-ai-token-302476176.html
Synaptogenix Inc Ordinary Shares
January 3, 2025  |  morningstar.comM
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
December 20, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-board-of-directors-forms-special-committee-to-explore-value-creation-opportunities-utilizing-balance-sheet-strength-302336765.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$1.33 -0.06 (-4.32%)
As of 04:00 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.69 +0.27 (+19.01%)
As of 04:00 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Optimi Health NASDAQ:OPTH

$4.84 -0.11 (-2.22%)
As of 04:00 PM Eastern

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. Optimi Health Corp. is based in VANCOUVER, BC.

Synaptogenix stock logo

Synaptogenix NASDAQ:TAOX

$4.80 +0.23 (+5.03%)
As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas